|
ONCOLOGY. Vol. 24 No. 1 Supplement Risk Assessment in Stage II Colorectal Cancer
By John L. Marshall, MD1 |
January 25, 2010
1Professor of Medicine and Oncology, Chief, Division of Hematology/Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
Financial Disclosure: The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article. This supplement and associated publication costs were funded by Genomic Health. This supplement and associated publication costs were funded by Genomic Health.
Risk Assessment in Stage II Colon Cancer
REFERENCES
1. QUASAR Collaborative Group, Gray R, Barnwell J, McConkey C, et al: Adjuvant chemotherapy vs obvservation in patients with colorectal cancer: A randomized study. Lancet 270:2020-2029. 2. Whelan T, Sawka C, Levine M, et al: Helping patients make informed choices: A randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95(8):581-587, 2003. 3. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319(9):525-532, 1988. 4. Roth AD, Tejpar S, Yan P, et al: Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial (abstract 4002). J Clin Oncol 27(suppl 15s):2009. 5. Nash GM, Gimbel M, Cohen AM, et al: KRAS mutation and microsatellite instability: Two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol 2009 Oct 8 [Epub ahead of print]. 6. Wright FC, Law CH, Berry S, et al: Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol 99(4):248-255, 2009. 7. Johnson PM, Porter GA, Ricciardi R, et al: Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24(22):3570-3575, 2006. 8. Carlson MR: Previstage GCC colorectal cancer staging test: A new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther 13(1):11-14, 2009. 9. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21(4):369-373, 2009. 10. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247-257, 2003. 11. Tejpar S, Bosman F, Delorenzi M, et al: Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) (abstract 4001). J Clin Oncol 27(suppl 15s):2009. 12. Mina L, Soule SE, Badve S, et al: Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 103(2):197-208, 2007. 13. Paik S: Molecular assays to predict prognosis of breast cancer. Clin Adv Hematol Oncol 5(9):681-682, 2007. 14. Kerr D, Gray R, Quirke P, et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study (abstract 4000). J Clin Oncol 27(suppl 15s):2009. 15. Glas AM, Roepman P, Salazar R, et al: Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients (abstract 4036). J Clin Oncol 27(suppl 15s):2009. |
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office. Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003. Finding Physician Work-Life Balance in the Small Moments Jennifer Frank, MD, May 21, 2013 At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs. Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation. Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
|
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy
